Julien Masliah-Planchon
PSL Research University
Publications 8
#1Aurelie Moreira (Curie Institute)
#2Julien Masliah-Planchon (PSL Research University)H-Index: 2
Last.Maud Kamal (Curie Institute)H-Index: 11
view all 23 authors...
Abstract Background A randomised trial SHIVA01 compared the efficacy of matched molecularly targeted therapy outside their indications based on a prespecified treatment algorithm versus conventional chemotherapy in patients with metastatic solid tumours who had failed standard of care. No statistical difference was reported between the two groups in terms of progression-free survival (PFS), challenging treatment algorithm. The European Society for Medical Oncology (ESMO) Scale for Clinical Actio...
#1Adeline Morel (PSL Research University)H-Index: 1
#2Julien Masliah-Planchon (PSL Research University)H-Index: 2
Last.Maud Kamal (Curie Institute)H-Index: 11
view all 10 authors...
#1Karolina Nemes (Boston Children's Hospital)H-Index: 4
#2Nathalie Clement (PSL Research University)H-Index: 10
Last.Christoph Frühwald (Boston Children's Hospital)
view all 35 authors...
#1L. BazireH-Index: 3
Last.Bruno BuecherH-Index: 24
view all 5 authors...
#1Clémence Basse (Curie Institute)H-Index: 2
#2Claire Morel (Curie Institute)H-Index: 2
Last.Maud Kamal (Curie Institute)H-Index: 11
view all 34 authors...
Background High throughput molecular screening techniques allow the identification of multiple molecular alterations, some of which are actionable and can be targeted by molecularly targeted agents (MTA). We aimed at evaluating the relevance of using this approach in the frame of Institut Curie Molecular Tumor Board (MTB) to guide patients with cancer to clinical trials with MTAs. Patients and methods We included all patients presented at Institut Curie MTB from 4 October 2014 to 31 October 2017...
2 CitationsSource
Purpose To identify the incidence of patients with perihippocampal metastases to assess the risk of brain relapse when sparing the hippocampal area. Medulloblastoma (MB) represents 20% of pediatric brain tumors. For high-risk MB patients, the 3- to 5-year event-free survival rate has recently improved from 50% to >76%. Many survivors, however, experience neurocognitive side effects. Several retrospective studies of patients receiving whole brain irradiation (WBI) have suggested a relationship be...
2 CitationsSource
#1Philipp Euskirchen (Charité)H-Index: 1
#2Franck Bielle (University of Paris)H-Index: 14
Last.Ahmed Idbaih (University of Paris)H-Index: 43
view all 13 authors...
Molecular classification of cancer has entered clinical routine to inform diagnosis, prognosis, and treatment decisions. At the same time, new tumor entities have been identified that cannot be defined histologically. For central nervous system tumors, the current World Health Organization classification explicitly demands molecular testing, e.g., for 1p/19q-codeletion or IDH mutations, to make an integrated histomolecular diagnosis. However, a plethora of sophisticated technologies is currently...
28 CitationsSource